Brominated trimetrexate analogues as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase

Journal of Heterocyclic Chemistry

Volumn 33, Issue 6, 1996, Pages 1959-1966

  Rosowsky, Andre ^a   Mota, Clara E ^a   Queener, Sherry F ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; ENZYME INHIBITOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PNEUMOCYSTIS CARINII; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; TOXOPLASMA GONDII;

EID: 0030512143     PISSN: 0022152X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jhet.5570330665     Document Type: Article

References (37)

1. J. Falloon and H. Masur, in AIDS Etiology, Diagnosis, Treatment and Prevention, V. T. DeVita, S. Hellman and S. A. Rosenberg, eds, Lippincott, Philadelphia, 1992, pp 157-166.
2. C. A. Hunter and J. S. Remington, J. Infect. Dis., 170, 1057 (1994).
3. R. F. Miller and D. M. Mitchell, Thorax, 50, 191 (1995).
4. G. Nash, J. W. Said and U. DeGirolami, Modern Pathology, 8, 199 (1995).
5. B. Danemann, J. A. McCutchan, D. M. Israelski, D. Antonikis, C. Leport, B. J. Luft, J. Nussbaum, N. Clumeck, P. Morlat, J. Chiu, J.-L. Vildé, M. Orellana, D. Feigal, A. Bartok, P. Heseltine, J. Leedom, J. S. Remington and the California Collaborative Treatment Group, Ann. Intern Med, 116, 33 (1992).
6. N. C. Klein, F. P. Duncanson, T. H. Lenox, C. Forszpaniak, C. B. Sherer, H. Quentzel, M. Nunez, M. Suarez, O. Kawwaff, A. Pitta-Alvarez, K. Freeman and G. P. Wormser, AIDS, 6, 301 (1992).
7. H. R. Chang, D. Arsenijevic, R. Comte, A. Polak, R. L. Then and J.-C. Pèchere, Antimicrob. Agents Chemother., 38, 1803 (1994).
8. E. F. Elslager, J. L. Johnson and L. M. Werhel, J. Med. Chem., 26, 1753 (1983).
9. J. T. Lin and J. R. Bertino, Cancer Investig., 9, 159 (1991).
10. D. E. Seitz, Cancer Investig., 12, 657 (1994).
11. H. Masur, M. A. Polis, C. U. Tuazon, D. Ogata-Arakaki, J. A. Kovacs, D. Katz, D. Hilt, T. Simmons, I. Feuerstein, B. Lundgren, H. C. Lane, B. A. Chabner and C. A. Allegra, J. Infect. Dis., 167, 1422 (1993).
12. F. R. Sattler, P. Frame, R. Davis, L. Nichols, B. Shelton, B. Akil, R. Baughman, C. Hughlett, W. Weiss, C. T. Boylen, C. van der Horst, J. Black, W. Powderly, R. T. Steigbigel, J. M. Leedom, H. Masur, J. Feinberg and the AIDS Clinical Trials Group 029/031 Research Team, J. Infect. Dis., 170, 165 (1994).
13. S. F. Queener, M. S. Bartlett, M. A. Jay, M. M. Durkin and J. W. Smith, Antimicrob. Agents Chemother., 31, 1323 (1987).
14. J. A. Kovacs, C. J. Allegra, J. C. Swan, J. C. Drake, J. E. Parillo, B. A. Chabner and H. Masur, Antimicrob. Agents Chemother., 32, 430 (1988).
15. C. J. Allegra, J. A. Kovacs, J. C. Drake, J. C. Swan, B. A. Chabner and H. Masur, J. Clin. Invest., 79, 478 (1987).
16. M. C. Broughton and S. F. Queener, Antimicrob. Agents Chemother., 35, 1348 (1991).
17. L.-C. Chio and S. F. Queener, Antimicrob. Agents Chemother., 37, 1914 (1993).
18. J. R. Piper, C. A. Johnson, C. A. Hosmer, R. L. Carter, E. R. Pfefferkorn, S. E. Borotz and S. F. Queener, Adv. Exptl. Biol. Med, 338, 429 (1993).
19. A. Rosowsky, C. E. Mota, J. E. Wright, J. H. Freisheim, J. J. Heusner, J. J. McCormack and S. F. Queener, J. Med. Chem., 36, 3103 (1993).
20. A. Rosowsky, C. E. Mota, J. E. Wright and S. F. Queener, J. Med. Chem., 37, 4522 (1994).
21. A. Rosowsky, C. E. Mota and S. F. Queener, J, Heterocyclic Chem., 32, 335 (1995).
22. A. Rosowsky, C. E. Mota, S. F. Queener, M. Waltham, E. Ercikan-Abali and J. R. Bertino, J. Med. Chem., 38, 745 (1995).
23. A. Rosowsky, R. A. Forsch and S. F. Queener, J. Med. Chem., 38, 2615 (1995).
24. A. Gangjee, R. Devraj and F.-T. Lin, J. Heterocyclic Chem., 28, 1747 (1991).
25. A. Gangjee, J. Shi, S. F. Queener, L. R. Barrows and R. L. Kisliuk, J. Med. Chem., 36, 3437 (1993).
26. A. Gangjee, R. Devraj, J. J. McGuire, R. L. Kisliuk, S. F. Queener and L. R. Barrows, J. Med. Chem., 37, 1169 (1994).
27. A. Gangjee, F. Mavandadi, S. F. Queener and J. J. McGuire, J. Med. Chem., 38, 2158 (1995).
28. A. Gangjee, R. Devraj, J. J. McGuire and R. L. Kisliuk, J. Med. Chem., 38, 3798 (1995).
29. A. Rosowsky, J. H. Freisheim, J. B. Hynes, S. F. Queener, M. Bartlett, J. W. Smith, H. Lazarus and E. J. Modest, Biochem. Pharmacol., 38, 2677 (1989).
30. R. L. Then, P. G. Hartman, I. Kompis and D. Santi, Adv. Exptl. Biol. Med., 338, 533 (1993).
31. A. Rosowsky, J. B. Hynes and S. F. Queener, Antimicrob. Agents Chemother., 39, 79 (1995).
32. A. M. Warshawski and A. I. Meyers, J. Am. Chem. Soc., 112, 8090 (1990).
33. K. Gewald, Chem. Ber., 98, 3571 (1965).
34. 1H nmr analysis. When as little as 1% of the dibromide is present in subsequent reactions such as those leading to 6b, 7b, or 8, the elemental analysis for bromine may be high even though carbon, hydrogen, and nitrogen analyses fall within ±0.4% of theoretical values. An alternative route to 19 which can avoid this problem is to subject 2-bromo-3,4,5-trimethoxybenzamide to Hofmann rearrangement followed by hydrolysis as described in reference 35.
35. G. P. Schiemenz and H. Englehard, Chem. Ber., 92, 862 (1959).
36. J. Davoll and A. M. Johnson, J. Chem. Soc., 997 (1970).
37. J. B. Hynes, A. Tomazic, C, A. Parrish and O. S. Fetzer, J. Heterocyclic Chem., 28, 1357 (1991).